Nomura Holdings Inc vs Stryker Corporation — how do they compare? Nomura Holdings Inc trades at $10.84 (market cap $31.31B), while Stryker Corporation trades at $276.2 (market cap $106.03B). The key difference: Stryker Corporation is far larger — about 3.4× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| NMR | SYK | |
|---|---|---|
Market Cap | $31.31B | $106.03B |
Sector | Financials | Technology |
52-Week High | $10.65 | $388.79 |
52-Week Low | $6.73 | $275.39 |
Dividend Yield | 3.05% | 1.27% |
Enterprise Value | — | $117.50B |
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, down 0.19% on the day, with a bullish technical signal driven by moving averages. Recent earnings show mixed quarterly performance but strong annual growth, with revenue reaching $1.66 trillion in 2025 and net income margin at 20.4%. The stock is supported by positive momentum coverage and a solid ROE of 11.03%.
Outlook remains favorable due to valuation metrics like a P/E of 12.46 and bullish analyst sentiment, though risks include volatile cash flows and rising debt-to-asset ratios. Investment opportunity lies in continued wholesale segment growth and ROE expansion, balanced by execution risks in a competitive financial sector.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Trailing returns across standard periods
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →